Evidence map›Paper›PMID 39813767›Full record

ArticleTranslational oncology2025

Combined anti-leukemic effect of gilteritinib and GSK-J4 in FLT3-ITD

Qi Zhou, Yongyu Guan, Pingping Zhao, Huiyuan Chu, Yaming Xi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qi ZhouThe First Clinical Medical College of Lanzhou University, Lanzhou 730000, China.
Yongyu GuanClinical laboratory, Gansu Provincial Maternal and Child Health Care Hospital, Lanzhou 730000, China.
Pingping ZhaoThe First Clinical Medical College of Lanzhou University, Lanzhou 730000, China.
Huiyuan ChuSchool of Public Health, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China.
Yaming XiThe First Clinical Medical College of Lanzhou University, Lanzhou 730000, China; Department of Hematology, The First Hospital of Lanzhou University, Lanzhou 730000, China. Electronic address: xiyaming022@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gilteritinib treats acute myeloid leukemia (AML) with the FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation. Dysregulation of histone modification affects the genesis and progression of AML. Strategies targeting key histone regulators have not been applied to the treatment of AML. Lysine demethylase 6B (KDM6B) is dysregulated in a variety of cancers and regulates the expression of oncogenes, which has potential in anticancer therapy. We explored whether GSK-J4 (an inhibitor of the demethylase KDM6B) has an anti-leukemic effect in the gilteritinib treatment of FLT3-ITD

Indexed as

Acute myeloid leukemiaCombination therapyFLT3-ITDGilteritinibGSK-J4

Identifiers

PMID39813767
PMCPMC11783125

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.